Traws Pharma (TRAW) Enterprise Value (2016 - 2025)
Traws Pharma (TRAW) has disclosed Enterprise Value for 14 consecutive years, with -$6.4 million as the latest value for Q3 2025.
- On a quarterly basis, Enterprise Value fell 18.67% to -$6.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.4 million, a 18.67% decrease, with the full-year FY2024 number at -$21.3 million, down 2.48% from a year prior.
- Enterprise Value was -$6.4 million for Q3 2025 at Traws Pharma, up from -$13.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.4 million in Q3 2024 to a low of -$59.4 million in Q3 2021.
- A 5-year average of -$31.1 million and a median of -$29.7 million in 2023 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 189.46% in 2021, then skyrocketed 78.57% in 2024.
- Traws Pharma's Enterprise Value stood at -$55.1 million in 2021, then increased by 29.62% to -$38.8 million in 2022, then surged by 46.28% to -$20.8 million in 2023, then decreased by 2.48% to -$21.3 million in 2024, then surged by 69.91% to -$6.4 million in 2025.
- Per Business Quant, the three most recent readings for TRAW's Enterprise Value are -$6.4 million (Q3 2025), -$13.1 million (Q2 2025), and -$15.9 million (Q1 2025).